presentation
Loading viewer...
investor_presentation
Format: PDF investor_presentation
Mineralys Therapeutics presents lorundrostat, a selective aldosterone synthase inhibitor targeting hypertension, chronic kidney disease, and heart failure. The clinical-stage biotech company reports proof-of-concept data demonstrating substantial blood pressure reduction and announces pivotal trial programs with readouts expected in 2025.
investor_presentation
21 Pages
investor_presentation
23 Pages
Tungsten Corporation PLC
Regeneron Pharmaceuticals Investor Presentation — November 2018
investor_presentationinvestor_presentation
33 Pages
Regeneron Pharmaceuticals, Inc.
Natural Grocers Investor Presentation August 2019
investor_presentationinvestor_presentation
23 Pages
Natural Grocers by Vitamin Cottage, Inc.
